Aastrom Biosciences, Inc. Added to Russell 3000 Index
28 June 2005 - 11:00PM
PR Newswire (US)
Aastrom Biosciences, Inc. Added to Russell 3000 Index ANN ARBOR,
Mich., June 28 /PRNewswire-FirstCall/ -- Aastrom Biosciences, Inc.
(NASDAQ:ASTM) announced today that it was added to the Russell
3000(R) Index effective at the close of market on Friday, June 24,
2005. The Russell 3000 Index measures the performance of the 3,000
largest U.S. companies based on total market capitalization.
Membership in the Russell 3000, which remains in place for one
year, means automatic inclusion in other Russell indexes. Russell
determines membership for its equity indexes primarily by objective
market capitalization rankings. Russell indexes are widely used by
investment managers and institutional investors for index funds and
as benchmarks for investment strategies. Investment managers who
oversee Russell's funds purchase shares of member stocks according
to each company's weighting in a particular index. About Russell
Russell, a global leader in multi-manager investment services,
provides investment products and services in more than 39
countries. Russell manages more than $135 billion in assets and
advises clients worldwide representing $2.3 trillion. Founded in
1936, Russell is a subsidiary of Northwestern Mutual and is
headquartered in Tacoma, Wash., with additional offices in New
York, Toronto, London, Paris, Singapore, Sydney, Auckland and
Tokyo. For more information, go to http://www.russell.com/. About
Aastrom Biosciences, Inc. Aastrom Biosciences, Inc. (NASDAQ:ASTM)
is developing patient-specific products for the repair or
regeneration of human tissues, utilizing the Company's proprietary
adult stem cell technology. Aastrom's strategic position in the
tissue regeneration sector is enabled by its proprietary Tissue
Repair Cells (TRCs), a mix of bone marrow-derived adult stem and
progenitor cells, and the AastromReplicell(R) System, an
industry-unique automated cell production platform used to produce
cells for clinical use. TRCs are the core component of the products
Aastrom is developing for severe bone fractures, ischemic vascular
disease, jaw reconstruction and spine fusion, with Phase I/II level
clinical trials active in the U.S. and EU for some of these
indications. For more information, visit Aastrom's website at
http://www.aastrom.com/. This document contains forward-looking
statements, including without limitation, statements concerning
planned clinical trials, product development objectives, potential
product applications, and potential advantages of Tissue Repair
Cells (TRCs) and the AastromReplicell(R) System, which involve
certain risks and uncertainties. The forward-looking statements are
also identified through use of the word "plan," and other words of
similar meaning. Actual results may differ significantly from the
expectations contained in the forward-looking statements. Among the
factors that may result in differences are clinical trial results,
potential product development difficulties, the effects of
competitive therapies, regulatory approval requirements, the
availability of financial and other resources and the allocation of
resources among different potential uses. These and other
significant factors are discussed in greater detail in Aastrom's
Annual Report on Form 10-K and other filings with the Securities
and Exchange Commission. CONTACTS: Kris M. Maly or Cameron
Associates Becky Anderson Kevin McGrath -- Institutions Investor
Relations Department Phone: (212) 245-4577 Aastrom Biosciences,
Inc. Alyson Nikulicz -- Media Phone: (734) 930-5777 Phone: (212)
554-5464 DATASOURCE: Aastrom Biosciences, Inc. CONTACT: Kris M.
Maly or Becky Anderson, Investor Relations Department of Aastrom
Biosciences, Inc., +1-734-930-5777; or Kevin McGrath, Institutions,
+1-212-245-4577, or Alyson Nikulicz, Media, +1-212-554-5464 Web
site: http://www.aastrom.com/ http://www.russell.com/
Copyright
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024